These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 16989623)

  • 1. Recombinant protective antigen 102 (rPA102): profile of a second-generation anthrax vaccine.
    Keitel WA
    Expert Rev Vaccines; 2006 Aug; 5(4):417-30. PubMed ID: 16989623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anthrax prevention and treatment: utility of therapy combining antibiotic plus vaccine.
    Klinman DM; Yamamoto M; Tross D; Tomaru K
    Expert Opin Biol Ther; 2009 Dec; 9(12):1477-86. PubMed ID: 19769541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mouse model characterisation for anthrax vaccine development: comparison of one inbred and one outbred mouse strain.
    Flick-Smith HC; Waters EL; Walker NJ; Miller J; Stagg AJ; Green M; Williamson ED
    Microb Pathog; 2005 Jan; 38(1):33-40. PubMed ID: 15652293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immunogenicity of the recombinant Bacillus strains with cloned gene of biosynthesis of protective antigen against Bacillus anthracis].
    Mikshis NI; Kudriavtseva OM; Bolothikova MF; Shulepov DV; Novikova LV; Popov IuA; Shchukovskaia TN; Drozdov IG; Kutyrev VV
    Mol Gen Mikrobiol Virusol; 2007; (3):15-21. PubMed ID: 17886469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial.
    Gorse GJ; Keitel W; Keyserling H; Taylor DN; Lock M; Alves K; Kenner J; Deans L; Gurwith M
    Vaccine; 2006 Aug; 24(33-34):5950-9. PubMed ID: 16797805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Past, imminent and future human medical countermeasures for anthrax.
    Baillie LW
    J Appl Microbiol; 2006 Sep; 101(3):594-606. PubMed ID: 16907809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms.
    Mikszta JA; Sullivan VJ; Dean C; Waterston AM; Alarcon JB; Dekker JP; Brittingham JM; Huang J; Hwang CR; Ferriter M; Jiang G; Mar K; Saikh KU; Stiles BG; Roy CJ; Ulrich RG; Harvey NG
    J Infect Dis; 2005 Jan; 191(2):278-88. PubMed ID: 15609239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative vaccine efficacy of different isoforms of recombinant protective antigen against Bacillus anthracis spore challenge in rabbits.
    Ribot WJ; Powell BS; Ivins BE; Little SF; Johnson WM; Hoover TA; Norris SL; Adamovicz JJ; Friedlander AM; Andrews GP
    Vaccine; 2006 Apr; 24(17):3469-76. PubMed ID: 16519970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparability of ELISA and toxin neutralization to measure immunogenicity of Protective Antigen in mice, as part of a potency test for anthrax vaccines.
    Parreiras PM; Sirota LA; Wagner LD; Menzies SL; Arciniega JL
    Vaccine; 2009 Jul; 27(33):4537-42. PubMed ID: 19501205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A recombinant 63-kDa form of Bacillus anthracis protective antigen produced in the yeast Saccharomyces cerevisiae provides protection in rabbit and primate inhalational challenge models of anthrax infection.
    Hepler RW; Kelly R; McNeely TB; Fan H; Losada MC; George HA; Woods A; Cope LD; Bansal A; Cook JC; Zang G; Cohen SL; Wei X; Keller PM; Leffel E; Joyce JG; Pitt L; Schultz LD; Jansen KU; Kurtz M
    Vaccine; 2006 Mar; 24(10):1501-14. PubMed ID: 16271808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity in mice of anthrax recombinant protective antigen in the presence of aluminum adjuvants.
    Berthold I; Pombo ML; Wagner L; Arciniega JL
    Vaccine; 2005 Mar; 23(16):1993-9. PubMed ID: 15734073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anthrax, toxins and vaccines: a 125-year journey targeting Bacillus anthracis.
    Tournier JN; Ulrich RG; Quesnel-Hellmann A; Mohamadzadeh M; Stiles BG
    Expert Rev Anti Infect Ther; 2009 Mar; 7(2):219-36. PubMed ID: 19254170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The US capitol bioterrorism anthrax exposures: clinical epidemiological and immunological characteristics.
    Doolan DL; Freilich DA; Brice GT; Burgess TH; Berzins MP; Bull RL; Graber NL; Dabbs JL; Shatney LL; Blazes DL; Bebris LM; Malone MF; Eisold JF; Mateczun AJ; Martin GJ
    J Infect Dis; 2007 Jan; 195(2):174-84. PubMed ID: 17191162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective activity and immunogenicity of two recombinant anthrax vaccines for veterinary use.
    Fasanella A; Tonello F; Garofolo G; Muraro L; Carattoli A; Adone R; Montecucco C
    Vaccine; 2008 Oct; 26(45):5684-8. PubMed ID: 18775462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults.
    Campbell JD; Clement KH; Wasserman SS; Donegan S; Chrisley L; Kotloff KL
    Hum Vaccin; 2007; 3(5):205-11. PubMed ID: 17881903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Progress on the vaccine for anthrax].
    Zhan DW; Wang P; Wang LC; Zhang ZS
    Wei Sheng Wu Xue Bao; 2005 Feb; 45(1):149-52. PubMed ID: 15847185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasmid-based vaccination with candidate anthrax vaccine antigens induces durable type 1 and type 2 T-helper immune responses.
    Zhang Y; Qiu J; Zhou Y; Farhangfar F; Hester J; Lin AY; Decker WK
    Vaccine; 2008 Jan; 26(5):614-22. PubMed ID: 18166249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of safety and immunogenicity of an Escherichia coli-derived recombinant protective antigen (rPA) vaccine to prevent anthrax in adults.
    Brown BK; Cox J; Gillis A; VanCott TC; Marovich M; Milazzo M; Antonille TS; Wieczorek L; McKee KT; Metcalfe K; Mallory RM; Birx D; Polonis VR; Robb ML
    PLoS One; 2010 Nov; 5(11):e13849. PubMed ID: 21079762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nasal immunization with the mixture of PA63, LF, and a PGA conjugate induced strong antibody responses against all three antigens.
    Sloat BR; Shaker DS; Le UM; Cui Z
    FEMS Immunol Med Microbiol; 2008 Mar; 52(2):169-79. PubMed ID: 18194342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineered chloroplasts as vaccine factories to combat bioterrorism.
    Streatfield SJ
    Trends Biotechnol; 2006 Aug; 24(8):339-42. PubMed ID: 16815579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.